Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -25.05% is 59% above its 5-year average of -61.83%, near the high end of its 5-year range (-202.70%–-1.95%).
21.66% below its 12-month average of -20.59%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -14.90%.
EBITDA MARGIN
-25.05%
EBITDA MARGIN AVG TTM
-20.59%
EBITDA MARGIN AVG 3Y
-33.05%
EBITDA MARGIN AVG 5Y
-61.83%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-21.66%
CURRENT VS 3Y AVG
+24.21%
CURRENT VS 5Y AVG
+59.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Biodesix, Inc.
Market Cap
$236.56M
EBITDA Margin
-25.05%
TTM Avg
-20.59%
3Y Avg
-33.05%
5Y Avg
-61.83%
Market Cap
$239.45M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$244.25M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
Market Cap
$244.56M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$228.41M
EBITDA Margin
29.55%
TTM Avg
-2937.39%
3Y Avg
-39292.92%
5Y Avg
-29539.33%
Market Cap
$247.23M
EBITDA Margin
-100.05%
TTM Avg
-392.29%
3Y Avg
-392.29%
5Y Avg
-392.29%
Market Cap
$247.45M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biodesix, Inc. (BDSX) | $236.56M | -25.05% | -20.59% | -33.05% | -61.83% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| High Tide Inc. (HITI)vs › | $239.89M | 1.66% | 3.74% | -1.53% | 0.81% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 10.49% | 1.20% | -4.19% | -40.04% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.56M | 6.37% | -0.39% | -2.45% | 1.13% |
| Keros Therapeutics, Inc. (KROS)vs › | $228.41M | 29.55% | -2937.39% | -39292.92% | -29539.33% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $247.23M | -100.05% | -392.29% | -392.29% | -392.29% |
| InflaRx N.V. (IFRX)vs › | $247.45M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
Gross Margin
82.5%
EBITDA Margin
-25.1%
Operating Margin
-31.4%
Net Margin
-27.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -14.90% |
| 2026-03-31 | -18.71% |
| 2025-12-31 | -1.95% |
| 2025-09-30 | -26.03% |
| 2025-06-30 | -41.37% |
| 2025-03-31 | -42.64% |
| 2024-12-31 | -25.70% |
| 2024-09-30 | -39.52% |
| 2024-06-30 | -38.59% |
| 2024-03-31 | -65.45% |
| 2023-12-31 | -37.78% |
| 2023-09-30 | -43.98% |
| 2023-06-30 | -80.10% |
| 2023-03-31 | -163.74% |
| 2022-12-31 | -127.45% |
| 2022-09-30 | -80.54% |
| 2022-06-30 | -93.88% |
| 2022-03-31 | -202.70% |
| 2021-12-31 | -149.83% |
| 2021-09-30 | -188.19% |
| 2021-06-30 | -82.54% |
| 2021-03-31 | -16.76% |
| 2020-12-31 | -7.12% |
| 2020-09-30 | -59.36% |
| 2020-06-30 | -115.73% |
| 2020-03-31 | -151.96% |
| 2019-12-31 | -34.23% |
| 2019-09-30 | -211.31% |
| 2019-06-30 | -85.06% |
| 2019-03-31 | -85.06% |
| 2018-06-30 | -79.88% |
| 2018-03-31 | -79.88% |
